Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28434500 | 0.90 | CA2 (0.51) | CTSLCTSSCASP3CA2CTSB | |
| SCHEMBL6558624 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL3949229 | 0.84 | ATM (0.54) | CTSLCTSSCASP3CA2CTSB | |
| SCHEMBL10421483 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL9656905 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL11573515 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL4399079 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL9789291 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL1132569 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK | |
| SCHEMBL1132567 | 0.84 | CTSL (0.56) | CTSLCTSSCTSBATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | CTSL 368/4885CTSS 524/4885CASP3 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.